

Cough · 1: Chronic cough in adults

A H Morice, J A Kastelik

Thorax 2003;58:901–907

The investigation and treatment of chronic cough in adults is generally rewarding, provided there is an understanding of its aetiology, particularly when it arises from sites outside the respiratory tract.

Chronic cough is a common diagnostic and therapeutic problem. The exact prevalence has proved difficult to estimate and recurrent cough is reported by 3–40% of the population.^{1–4} The results of questionnaire surveys such as these are clearly influenced by the population studied and the question posed. In a postal and telephone survey of over 11 000 patients from four general practices in south east England, cough was reported every day or on over half of the days of the year by 14% of men and 10% of women.² A survey of 18 277 subjects aged 20–48 years from 16 countries worldwide reported nocturnal cough in 30%, productive cough in 10%, and non-productive cough in 10%.³ In this study the very high prevalence of nocturnal cough arose because a positive response to the question “Have you been woken by an attack of coughing at any time in the last 12 months?” was taken as indicating the symptom. However, since acute cough—by far the commonest symptom for which medical advice is sought⁵—could also lead to a positive response, significant nocturnal cough was probably overestimated in this study. Whatever the failings of individual surveys, chronic cough is clearly a very common symptom which, although associated with considerable morbidity, goes largely unheeded.

Unsurprisingly, cigarette smoking had a dose related influence on the prevalence of productive cough.³ In clinical practice, however, smokers readily ascribe their cough to tobacco and rarely seek medical advice specifically to combat this. As a consequence, the incidence of smoking related cough presenting as an isolated symptom in secondary care is low.² The reasons why patients seek advice regarding chronic cough are not fully understood, but may be related to worry about the cough.⁶ Often, cough related morbidity—in terms of sleep disturbance (either of the patient or their relatives), urinary incontinence in women, or syncope—drives the patient to consult.^{6–8} Indeed, chronic cough has been shown to be associated with a marked deterioration in quality of life which returns to normal on successful treatment.^{7–9}

In population surveys, men have reported cough more frequently.^{2 10 11} However, most patients referred to specialist cough clinics are women (table 1). This paradox may be explained by differences in smoking habit, but women also

appear to have an intrinsically heightened cough response. Inhalation cough challenge is augmented in both healthy female volunteers^{12–16} and female patients with chronic cough.¹⁷ A higher frequency of ACE inhibitor induced cough¹⁸ is also found in women, suggesting that any sex related difference is unlikely to be due to augmented deposition of tussive stimuli in women. A hormonal influence is inferred by the observation that cough reflex sensitivity is similar in boys and girls,¹⁹ but the reason for the marked sex difference in adults remains obscure.

Duration is important in determining the possible aetiology of cough. Classically, cough lasting less than 3 weeks has been considered as acute and that of more than 3 weeks duration has been defined as chronic.²⁰ In recent years there has been a tendency to redefine chronic cough as cough lasting more than 8 weeks and, for further clarification, the term “subacute cough” was proposed to describe cough lasting 3–8 weeks.²¹ While these definitions remain arbitrary, the concept of chronic cough remains clinically important. In this review we will describe the assessment and management of patients with chronic cough.

CLINICAL EXPERIENCE OF CHRONIC COUGH

Chronic cough has frequently been considered to be an intractable problem. Such despondency, however, is not supported by the experience of specialist cough clinics. In these tertiary referral centres, which presumably concentrate on the most difficult diagnostic problems, an accurate diagnosis leading to effective treatment is achieved in over 80% of patients. This contrasts markedly with the experience in non-specialist clinics.²² The main reason for this difference is a failure to consider the potential origin of cough as being outside the lower respiratory tract. Because cough may arise from anywhere in the distribution of the vagus, the full assessment of the patient with chronic cough relies on a multidisciplinary approach and close cooperation between gastroenterology and ENT departments, as well as respiratory medicine. If this approach is adopted, only a small number of patients with idiopathic cough remain in whom no diagnosis is determined.

SYSTEMATIC ASSESSMENT OF COUGH

Twenty years ago Irwin and colleagues suggested that the investigation of patients with chronic cough could be based on an “anatomical diagnostic protocol” and that, if such an approach was used, “the outcome of specific therapy, almost without exception, is successful and sustained”.²³ Our knowledge of the anatomical

See end of article for authors' affiliations

Correspondence to: Professor A H Morice, Academic Department of Medicine, Respiratory Medicine, University of Hull, Castle Hill Hospital, Castle Road, Cottingham HU16 5JQ, UK; a.h.morice@hull.ac.uk

Table 1 Most common causes of chronic cough in patients investigated in specialist clinics

Author	No patients (no female)	Improved	Diagnosis (% of total)			
			Asthma syndrome	GOR	Rhinitis	Most common other
Irwin <i>et al</i> ²³	49 (27)	98%	25	10	29	Chronic bronchitis (12%)
Poe <i>et al</i> ¹¹³	109 (68)	96%	36	0	8	Post infectious (27%)
Poe <i>et al</i> ³¹	139 (84)	88%	35	5	26	Idiopathic (12%)
Irwin <i>et al</i> ²⁷	102 (59)	99%	24	21	41	Chronic bronchitis (5%)
Hoffstein <i>et al</i> ¹¹⁴	228 (139)	91%	25	24	26	Post infectious (21%)
O'Connell <i>et al</i> ³⁰	87 (63)	68%	6	10	13	Idiopathic (22%)
Smyrniotis <i>et al</i> ⁸⁶	71 (32)	97%	24	15	40	Chronic bronchitis (11%)
Mello <i>et al</i> ⁹⁴	88 (64)	98%	14	40	38	Bronchiectasis (4%)
Marchesani <i>et al</i> ²⁸	92 (72)	91%	14	5	56	Chronic bronchitis (16%)
McGarvey <i>et al</i> ³²	43 (29)	82%	23	19	21	Idiopathic (18%)
Palombini <i>et al</i> ²⁶	78 (51)	—	59	41	58	Bronchiectasis (18%)
Brightling <i>et al</i> ²⁹	91 (—)	93%	31	8	24	Post viral (13%)
Simpson ¹⁵	86 (51)	92%	6	22	28	Post viral (13%)

GOR = gastro-oesophageal reflux.

and cellular basis for cough receptor stimulation has evolved since that time, both in terms of conditions known to cause cough and the mechanisms whereby the cough reflex is stimulated in disease. However, the concept of a logical diagnostic pathway leading to successful specific treatment remains the basis of the organisation of the specialist cough clinics reported in the literature. In the absence of such an approach, the diagnostic yield and outcome of treatment is poor.^{22–24}

Limited experience from general practice suggests that over 90% of patients with chronic cough, who represented approximately 6% of all new referrals, had their cough attributed to either bronchial hyperresponsiveness or upper airway disease.²⁵ In contrast, a survey from a general respiratory clinic revealed that over half the patients with cough had underlying lung disorders such as chronic obstructive pulmonary disease (COPD), bronchiectasis, pulmonary fibrosis, or lung cancer.²² Thus, when examining the evidence obtained from tertiary referral clinics, it is important to realise that many of the common respiratory disorders associated with chronic cough have been excluded by the referral pattern. The spectrum of patients described below does not represent the total population with chronic cough, and conditions such as bronchiectasis and lung cancer are underrepresented. This observation may also go some way to explain the large variation in the reported incidence of the three common syndromes associated with chronic cough (asthma, gastro-oesophageal reflux, and rhinitis; table 1).

Methodological differences in how a diagnosis is accepted as the cause of cough are also likely to be important. In the study by Palombini *et al*²⁶ patients underwent more than 12 different diagnostic procedures and were considered to be positive for a diagnosis if a test result was abnormal. Unsurprisingly, this approach led to the claim that multiple causes of cough could be identified in over 60% of patients. Even when the investigation is tailored to the presenting symptoms, multiple diagnoses are made. For example, Irwin *et al*²⁷ reported multiple aetiology for cough in a quarter of his patients. The more conservative approach of determining diagnosis, adopted particularly in European centres, has shown that in 89–100% of patients a single cause of chronic cough can be established.^{22–28–30} However, a concomitant increase has been observed in the number of patients with idiopathic cough. Whereas Irwin *et al*^{23–27} and Palombini *et al*²⁶ came to a diagnosis in all but one of 249 unselected patients, firstly Poe *et al*³¹ and subsequently several other groups^{28–32} have failed to achieve such diagnostic excellence, even when the anatomical diagnostic protocol was rigorously followed.

O'Connell *et al*³⁰ were the first to suggest that a different approach based on the empirical treatment of cough could

lead to an improved diagnostic yield. In this study patients were allotted treatment when intensive investigations had failed to provide a diagnosis. The finding that a number of patients did not achieve a primary diagnosis is perhaps unsurprising in the knowledge that more recent studies have described previously unrecognised causes of chronic cough such as eosinophilic bronchitis,²⁹ eosinophilic tracheobronchitis,³³ and oesophageal dysmotility.^{34–36} The plan of investigation used at that time would not have been capable of picking up these newly discovered associations and it is likely that those patients currently classed as having idiopathic cough will have as yet undiscovered syndromes.

Several investigators have attempted to enhance diagnosis with the evaluation of upper airway inflammation,³⁷ the analysis of induced sputum for cytokines, interleukins or TNF-alpha,³⁸ and the measurements of exhaled nitric oxide levels.³⁹ These efforts have, however, met with limited success. Conversely, it is possible that a simplified approach with a therapeutic trial as the main diagnostic arm of a cough clinic protocol may be successful. This strategy could be used earlier to provide a diagnosis without the need for specialised investigations. The approach of symptom led therapeutic trials requires a thorough knowledge of the likely aetiology and incidence of the various cough syndromes.

CHRONIC COUGH SYNDROMES

There are three common causes of chronic cough: asthma, oesophageal disease, and rhinitis. This "diagnostic triad"²⁶ contains the overwhelming majority of patients who suffer from chronic cough.

Asthma related syndromes

The diagnosis of asthma as provided in the UK guidelines relies on the evidence of variability of airflow obstruction, either spontaneous or pharmacologically induced.^{40–41} However, the US National Institutes of Health definition⁴² states that asthma is "a clinical syndrome characterised by increased responsiveness of the tracheobronchial tree to a variety of stimuli". This latter definition allows for asthma without airflow obstruction such as that which occurs in cough variant or, more accurately, cough predominant asthma. Our concentration on measures of variable airflow obstruction in the diagnosis of adult asthma has been led by practice in clinical trial design.⁴³ Here reversibility to salbutamol or diurnal variation in peak expiratory flow are almost universally used as entry criteria to establish the diagnosis. Reversibility to β agonists is very good for proving that patients have asthma but is not reflected in the generality of asthma patients. Indeed, less than 10% of an asthmatic population may exhibit spirometric reversibility

sufficient to satisfy the entry criteria for most clinical studies of asthma.⁴⁴

The problematic nature of defining asthma in epidemiology has been extensively discussed⁴⁵ and it is clear that no single test has sufficient sensitivity and specificity to diagnose reliably a syndrome with such protean manifestations.⁴⁶ This is particularly relevant when cough is the primary presenting complaint. The term “variant asthma” or “cough variant asthma” to describe asthma associated with cough was originally introduced by Glauser.⁴⁷ This entity was more clearly defined in 1979 by Corrao and colleagues who described six patients with chronic cough, bronchial hyperresponsiveness, and a response to anti-asthma medication but without wheezing and airflow obstruction.⁴⁸ Subsequently, the term “cough predominant asthma” was proposed by Pratter and colleagues⁴⁹ based on the suggestion that cough is not a separate entity but part of the spectrum of asthma together with dyspnoea and airflow obstruction. In our experience, this term more accurately describes the patients seen in clinical practice.

Niimi *et al*⁵⁰ demonstrated the presence of eosinophilic inflammation in cough predominant asthma and a further variant, eosinophilic bronchitis, is characterised by airway eosinophilia but without bronchial hyperresponsiveness. Originally described by Gibson and colleagues,⁵¹ eosinophilic bronchitis may be detected in patients with chronic cough where reliable sputum induction and analysis is available.^{29 37} Whether cough with sputum eosinophilia but without airflow reversibility or hyperresponsiveness is a form of asthma remains debatable. The different facets of the syndrome may be due to the differential location of inflammatory cells, particularly mast cells, within the airway.^{52 53} However the terms “eosinophilic bronchitis” and “cough predominant asthma” appear to be clinically useful (table 2).

All of these facets of the “cough/asthma syndrome” usually improve with inhaled corticosteroids. The early symptomatic response to inhaled corticosteroids in “classical asthma” may be delayed in chronic asthmatic cough.^{29 54} Similarly, in eosinophilic bronchitis significant improvements in cough threshold and sputum eosinophilia have been observed after 4 weeks of treatment with budesonide.⁵⁵ However, treatment may be required for several months before maximum improvement is observed. In this regard, cough may be similar to the slow improvement in airway hyperresponsiveness seen with inhaled corticosteroids in “classical asthma”.⁵⁶ This phenomenon of a delayed response is also true of treatment for the other cough syndromes.

Patients with possible asthmatic cough presenting to secondary care (in the UK) are almost invariably on inhaled corticosteroids, and a poor response may indicate the usual problems with asthma therapy. Everard’s “three Cs”⁵⁷ of competence, contrivance and compliance should be applied. An initial trial of prednisolone may be helpful.⁵⁸ Since bronchoconstriction is not usually a major feature, an alternative diagnostic strategy is to stop inhaled corticosteroids. A progressive worsening of cough, with or without deterioration in peak expiratory flow, confirms the diagnosis.

This also allows sputum examination since even moderate doses of inhaled corticosteroids cause a dramatic fall in the sputum eosinophil count.⁵⁹ The subsequent symptomatic improvement on reinstatement of treatment reinforces the diagnosis and is associated with an improvement in cough sensitivity (fig 1).

In patients who remain symptomatic on moderate doses of inhaled corticosteroids there is no clear evidence based strategy. Two recent studies reported on the effects of leukotriene receptor antagonists on the cough reflex.^{60 61} While zafirlukast had no effect on the normal cough response in classic asthma,⁶⁰ it showed marked antitussive effects in patients with cough predominant asthma.⁶¹ The fact that lipoxygenase products have been shown to have a major modulatory role on the putative VRI cough receptor⁶² may indicate a specific role for these agents in asthmatic cough. Fujimura *et al*^{33 63 64} have also described a response to antihistamines in a syndrome they termed eosinophilic tracheobronchitis or “atopic cough”.

As in all the conditions illustrated in table 2 cough improves with corticosteroids, the term “corticosteroid responsive cough” as used by Gibson and colleagues in the original paper describing eosinophilic bronchitis⁵¹ may provide a convenient simplification. However, it is important to realise that non-asthmatic cough could be steroid responsive, both in rhinitis and in gastro-oesophageal reflux (GOR). An increased eosinophil count can be seen in the bronchoalveolar lavage fluid of patients with GOR related cough⁶⁵ and airway inflammation is unsurprisingly seen in patients with reflux. This latter may be confirmed on direct examination of the endolarynx (fig 2). Thus, in patients with laryngopharyngeal reflux, erythema or, more commonly, oedema of the arytenoid, interarytenoid area, and laryngeal surface of the epiglottis is present, together with oedema of the vocal cords and Reinke’s space (lamina propria of the true vocal cords).^{66 67} These changes may lead to a characteristic obliteration of the ventricle, the groove between the true and false vocal cords.




Figure 1 Improvement in cough reflex sensitivity measured by citric acid cough challenge in response to inhaled corticosteroids in a patient with cough variant asthma.

Table 2 Corticosteroid responsive cough syndromes

Diagnosis	PEF variability	Bronchial hyperresponsiveness	Sputum eosinophilia
Classical asthma	Yes	Yes	Yes
Cough variant of asthma	No	Yes	Yes
Eosinophilic bronchitis	No	No	Yes




Figure 2 Oedema of the vocal cords, ventricles, and posterior commissurae seen during bronchoscopy in a patient with gastro-oesophageal reflux related chronic cough.

Chronic cough associated with gastro-oesophageal disorders

Gastro-oesophageal disease has been reported in 10–40% of patients with chronic cough. The pathophysiological mechanisms underlying this type of cough are not fully understood, but may include microaspiration of oesophageal contents into the larynx and tracheobronchial tree⁶⁸ or local irritation of cough receptors within the lower oesophagus.^{69–70} It has been reported that 75% of patients with oesophageal cough have cough as the sole presenting symptom.^{69–71} However, we suggest that a careful clinical history focused on assessment of reflux symptoms such as heartburn, dysphagia, dysphonia, globus, acid regurgitation, and a bitter taste in the mouth is helpful. An association of cough with food—either eating certain types of food or the act of eating itself via the pharyngo-oesophageal reflex—is typical.⁷² Cough which is precipitated by adopting an upright posture is characteristic of reflux since it is accompanied by relaxation of the lower oesophageal sphincter.⁷³ This history may be elicited by asking the patient when they start coughing in the morning at first waking, as Sir John Floyer observed in asthma,⁷⁴ or on rising, typically to go to the bathroom.

An objective measurement of reflux using ambulatory oesophageal 24 hour pH monitoring is required in a proportion of patients in whom no diagnostic clues can be obtained from the history. Not all patients who have positive 24 hour pH monitoring respond to antireflux therapy and, similarly, a negative study does not preclude a therapeutic response.^{75–78} An empirical trial with antireflux therapy has therefore been advocated.^{21–79} As in asthmatic cough, response may be delayed and treatment for at least 2 months with a high dose of a proton pump inhibitor may be required.

The gastroenterological definition of abnormality on 24 hour pH monitoring relies on a synthesis of the total number of reflux events, the fraction of time when pH <4, the number of events of pH <4 lasting longer than 4 minutes, and the longest upright and supine reflux events.^{80–81} In cough, however, such criteria may be irrelevant because even the briefest reflux event reaching the larynx could give rise to cough. Using the conventional parameters of abnormal oesophageal acidification, false negatives occur in a proportion of patients.⁶⁹ Indeed, in some patients with reflux disease fundoplication is successful despite failure with intensive acid suppression,⁸² indicating that mediators other than acid in the refluxate may be important in cough.

In chronic cough the temporal association with reflux is also relevant. The number of coughs induced by a reflux

event—that is, occurring simultaneously with or shortly after a fall in pH—should be measured.^{69–71–83} In an elegant experiment Ing *et al*⁷⁰ demonstrated this effect by infusion of acid into the lower oesophagus. In a proportion of patients, however, cough can also be induced by intra-oesophageal infusion of 0.9% saline.^{69–70} This supports the hypothesis that cough may be induced not only by acidification, but also by other stimuli. Abnormal oesophageal manometry such as low gastro-oesophageal sphincter pressure leading to volume reflux and disordered oesophageal peristalsis also contribute in patients with chronic cough.^{34–36} It is possible that the role of non-acid reflux may be further clarified by measuring oesophageal impedance.^{84–85}

Chronic cough associated with gastro-oesophageal disorders frequently improves with antireflux therapy.^{69–71} Conservative measures such as weight reduction, high protein low fat diet, elevation of the head of the bed, and lifestyle modification including avoidance of caffeine, smoking, and chocolate are often recommended, although the basis for this advice is unclear. H₂ antagonists,^{23–27–71} proton pump inhibitors,^{30–32–76} and prokinetic medication^{23–27–86} have been used, but proton pump inhibitors—particularly at high doses—seem superior in treating cough.^{49–79} In patients with abnormal oesophageal manometry but normal 24 hour pH monitoring, proton pump inhibitors also appear effective.³⁶

The three placebo controlled trials reported to date have confirmed that both H₂ antagonists and proton pump inhibitors correct chronic cough in patients with gastro-oesophageal reflux.^{75–77–78} These studies reported a relatively slow response in cough, ranging from 8 to 12 weeks. Occasionally, however, 6 months or longer may be required for the cough to improve.^{23–27} Unfortunately, antireflux agents do not fully suppress acid secretion and do not alter the frequency of reflux events.^{82–87} Antireflux surgery such as fundoplication may be successful in the face of an inadequate medical response.^{82–88} However, the role of surgery has yet to be fully evaluated.

Rhinitis, sinusitis, and postnasal drip

In contrast to the relative precision with which the asthma syndromes and oesophageal cough can be investigated, the association of chronic cough with upper airway disease frequently lacks objective verification. Many series, mainly from the US literature, report that postnasal drip syndrome (PNDS) is one of the most common causes of chronic cough.^{26–27–49–86} However, this term describes a symptom complex that does not have any objective or pathognomonic findings.²⁰ The diagnosis of PNDS rests on eliciting symptoms that include the sensation of “something dripping into the throat”, frequent throat clearing, nasal congestion or discharge.^{23–27} Such symptoms are common in non-coughing individuals and vary enormously in different societies. A large telephone survey of cold symptomatology found that over 50% of subjects contacted in the USA associated a cold with PNDS, whereas less than a quarter in the UK and virtually no respondents from Latin America and India admitted to the symptom (Dr Hull, Procter & Gamble, personal communication).

Rhinitis is a much simpler term describing the location of airway inflammation. Sinusitis is present clinically when there is facial pain and may be associated with mucosal thickening, opacification of a sinus or an air-fluid level, and response to antibiotics.^{28–30} Sinus imaging has been suggested to support the diagnosis.^{32–37–86} However, in the context of chronic cough, sinus imaging appears to be unhelpful and of low predictive value.^{32–89}

The common use of the term PNDS in cough has been led by clinicians who have observed that combinations of antihistamines and decongestants are effective in treating

some patients with chronic cough.²³⁻²⁷ Pratter *et al.*⁴⁹⁻⁸⁹ using a stepped approach that involved the initial treatment of all patients with chronic cough with antihistamine decongestants, diagnosed PNDS in over 80% of cases. Some of these patients were asymptomatic apart from cough and they proposed the term "silent" postnasal drip syndrome since cough was the sole manifestation of PNDS. Obviously there are many more explanations for this therapeutic success than PNDS. However, these observations underscore the importance of histamine in chronic cough, either through a central activity⁹⁰ or possibly due to its role in airway inflammation.⁹¹

A key question in cough associated with rhinitis is how the afferent sensory input generating the cough is developed. In animal studies no cough sensitive innervation can be seen above the larynx.⁹² Recently, based on the observation of a high frequency of asthma coexisting with allergic rhinitis, Grossman⁹³ introduced a concept of "one airway, one disease". Thus, upper and lower airway diseases are described as a continuum of inflammation involving one airway that may have a common origin for the underlying pathological process. In cough the coexistence of asthma and rhinitis has been reported for many years.^{23-27, 94} Whether upper airway disease contributes to cough via PNDS or is merely a marker remains uncertain.³² Some support for the "one airway, one disease" concept in the pathophysiology of cough was provided by the response to histamine H₁ antagonists and corticosteroids in patients with "atopic cough".³³⁻⁶⁴ Better clarification of the description of rhinitis associated cough based on a scheme such as the ARIA guidelines⁹⁵ needs to be developed.

OTHER CAUSES OF CHRONIC COUGH

Many other conditions can give rise to chronic cough. Typically, cough is the major component of a well recognised clinical syndrome such as chronic bronchitis, pulmonary fibrosis, or bronchiectasis. There are, however, a number of causes of cough which still provide diagnostic confusion.

ACE inhibitor cough

That a systemically active drug could cause cough as a side effect went unrecognised for many years.⁹⁶⁻⁹⁷ Cough associated with angiotensin converting enzyme (ACE) inhibition occurs in up to 15% of patients and has a very variable onset and offset.⁹⁸⁻⁹⁹ Because ACE inhibitors appear to alter the sensitivity of the cough reflex,¹⁰⁰ underlying subclinical cough such as that from reflux may now declare itself. Cessation of treatment with ACE inhibitors returns the cough reflex to normal,³⁰⁻⁹⁸ but the plasticity of the reflex varies and it may take several months for the cough to settle in some individuals.¹⁰¹ Several small scale studies have reported a beneficial effect from a variety of agents in ACE inhibitor induced cough.¹⁰²⁻¹⁰⁴ None have proved useful in clinical practice. The alteration in the sensitivity of the cough reflex precludes the full assessment of patients with cough while the patient remains on treatment. Indeed, alternative agents such as angiotensin II antagonists provide the beneficial effects of ACE inhibition without the tendency to cough.¹⁰⁵

Occupational exposure

Cough may be an important symptom in a number of occupational lung diseases, particularly asthma. Cough as an isolated finding may occur following chronic exposure to low molecular weight irritants. In a glass bottle factory workers exposed to hydrochloric acid and organic oils developed chronic cough without airways hypersensitivity to methacholine. Cough reflex hypersensitivity was demonstrated by inhalation challenge with capsaicin and citric acid.¹⁰⁶⁻¹⁰⁷

Post infectious cough

Occasionally, patients give a striking history of prolonged cough following a relatively minor respiratory tract infection. If recurrent, then anatomical lesions such as bronchiectasis need to be excluded. Some agents such as *Bordetella* species are notorious for causing prolonged cough and recent studies have suggested that, in adults, infection and repeat infection are relatively common.¹⁰⁸⁻¹⁰⁹

Systemic illness

A number of systemic disorders, either organ specific autoimmune diseases¹¹⁰ or vasculitic disorders,¹¹¹⁻¹¹² may present with cough. These illustrate the non-specific nature of cough as a response to airway inflammation.

CONCLUSION

The investigation and treatment of chronic cough is a rewarding and generally fruitful undertaking. By adopting an approach based on a careful history, simple investigations and therapeutic trials, dramatic improvements in quality of life can be achieved at little cost. The main reason for failure is a lack of understanding of the aetiology of cough, particularly when it arises from sites outside the respiratory tract.

Authors' affiliations

A H Morice, J A Kastelik, Academic Department of Medicine, Respiratory Medicine, University of Hull, Castle Hill Hospital, Cottingham HU16 5JQ, UK

REFERENCES

- 1 Loundon RG, Brown LC. Cough frequency in patients with respiratory disease. *Am Rev Respir Dis* 1967;**96**:1137-43.
- 2 Cullinan P. Persistent cough and sputum: prevalence and clinical characteristics in south east England. *Respir Med* 1992;**86**:143-9.
- 3 Janson C, Chinn S, Jarvis D, *et al.* Determinants of cough in young adults participating in the European Community Respiratory Health Survey. *Eur Respir J* 1991;**18**:647-54.
- 4 Di Pede C, Viegi G, Quackenboss JJ, *et al.* Respiratory symptoms and risk factors in an Arizona population sample of Anglo and Mexican-American whites. *Chest* 1991;**99**:916-22.
- 5 Schappert KT. *National Ambulatory Medical Care Survey: 1991 summary Advance Data*, 1993.
- 6 Cornford CS. Why patients consult when they cough: a comparison of consulting and non-consulting patients. *Br J Gen Pract* 1998;**48**:1751-4.
- 7 French CL, Irwin RS, Curley FJ, *et al.* Impact of chronic cough on quality of life. *Arch Intern Med* 1998;**158**:1657-61.
- 8 French CT, Irwin RS, Fletcher KE, *et al.* Evaluation of cough-specific quality of life questionnaire. *Chest* 2002;**121**:1123-31.
- 9 Thompson R, Kastelik JA, Ojoo JC, *et al.* Impact of chronic cough on health. *Thorax* 2001;**56**(Suppl III):iii71.
- 10 Littlejohns P, Ebrahim S, Anderson R. Prevalence and diagnosis of chronic respiratory symptoms in adults. *BMJ* 1989;**298**:1556-60.
- 11 Lambert PM, Reid DD. Smoking, air pollution, and bronchitis in Britain. *Lancet* 1970;**ii**:853-7.
- 12 Fujimura M, Sakamoto S, Kamio Y, *et al.* Sex difference in the inhaled tartaric acid cough threshold in non-atopic healthy subjects. *Thorax* 1990;**45**:633-4.
- 13 Fujimura M, Kasahara K, Yasui M, *et al.* Atopy in cough sensitivity to capsaicin and bronchial responsiveness in young females. *Eur Respir J* 1998;**11**:1060-3.
- 14 Dicipingaitis PV, Rauf K. The influence of gender on cough reflex sensitivity. *Chest* 1998;**113**:1319-21.
- 15 Fujimura M, Kasahara K, Kamio Y, *et al.* Female gender as a determinant of cough threshold to inhaled capsaicin. *Eur Respir J* 1996;**9**:1624-6.
- 16 Morice A, Kastelik JA, Thompson RH. Gender differences in airway behaviour. *Thorax* 2000;**55**:629.
- 17 Kastelik JA, Thompson R, Aziz I, *et al.* Sex related differences in cough reflex sensitivity in patients with chronic cough. *Am J Respir Crit Care Med* 2002;**166**:961-4.
- 18 Gibson GR. Enalapril-induced cough. *Arch Intern Med* 1989;**149**:2701-3.
- 19 Chang AB, Phelan PD, Sawyer SM, *et al.* Cough sensitivity in children with asthma, recurrent cough, and cystic fibrosis. *Arch Dis Child* 1997;**77**:331-4.
- 20 Irwin RS, Boulet LP, Cloutier MM, *et al.* Managing cough as a defense mechanism and as a symptom. A consensus panel report of the American College of Chest Physicians. *Chest* 1998;**114**:133-81S.
- 21 Irwin RS, Madison JM. The diagnosis and treatment of cough. *N Engl J Med* 2000;**343**:1715-21.

- 22 **McGarvey LPA**, Heaney LG, MacMahon J. A retrospective survey of diagnosis and management of patients presenting with chronic cough to a general chest clinic. *Int J Clin Pract* 1998;**52**:158–61.
- 23 **Irwin RS**, Corrao WM, Pratter MR. Chronic persistent cough in the adult: the spectrum and frequency of causes and successful outcome of specific therapy. *Am Rev Respir Dis* 1981;**123**:413–7.
- 24 **Puolijoki H**, Lahdensuo A. Causes of prolonged cough in patients referred to a chest clinic. *Ann Med* 1989;**21**:425–7.
- 25 **Kardos P**, Gebhardt T. Chronic persistent cough in general practice: diagnosis and therapy in 329 patients over the course of 2 years. *Pneumologie* 1996;**50**:437–41.
- 26 **Palombini BC**, Villanova CA, Araujo E, et al. A pathogenic triad in chronic cough: asthma, postnasal drip syndrome, and gastroesophageal reflux disease. *Chest* 1999;**116**:279–84.
- 27 **Irwin RS**, Curley FJ, French CL. Chronic cough. The spectrum and frequency of causes, key components of the diagnostic evaluation, and outcome of specific therapy. *Am Rev Respir Dis* 1990;**141**:640–7.
- 28 **Marchesani F**, Cecarini L, Pela R, et al. Causes of chronic persistent cough in adult patients: the results of a systematic management protocol. *Monaldi Arch Chest Dis* 1998;**53**:510–4.
- 29 **Brightling CE**, Ward R, Goh KL, et al. Eosinophilic bronchitis is an important cause of chronic cough. *Am J Respir Crit Care Med* 1999;**160**:406–10.
- 30 **O'Connell F**, Thomas VE, Pride NB, et al. Capsaicin cough sensitivity decreases with successful treatment of chronic cough. *Am J Respir Crit Care Med* 1994;**150**:374–80.
- 31 **Poe RH**, Harder RV, Israel RH, et al. Chronic persistent cough. Experience in diagnosis and outcome using an anatomic diagnostic protocol. *Chest* 1989;**95**:723–8.
- 32 **McGarvey LP**, Heaney LG, Lawson JT, et al. Evaluation and outcome of patients with chronic non-productive cough using a comprehensive diagnostic protocol. *Thorax* 1998;**53**:738–43.
- 33 **Fujimura M**, Ogawa H, Yasui M, et al. Eosinophilic tracheobronchitis and airway cough hypersensitivity in chronic non-productive cough. *Clin Exp Allergy* 2000;**30**:41–7.
- 34 **Knight RE**, Wells JR, Parrish RS. Esophageal dysmotility as an important cofactor in extraesophageal manifestations of gastroesophageal reflux. *Laryngoscope* 2000;**110**:1462–6.
- 35 **Fouad YM**, Katz PO, Hatlebakk JG, et al. Ineffective esophageal motility: the most common motility abnormality in patients with GERD-associated respiratory symptoms. *Am J Gastroenterol* 1999;**94**:1464–7.
- 36 **Kastelik JA**, Redington AE, Aziz I, et al. Abnormal oesophageal motility in patients with chronic cough. *Thorax* 2003;**58**:699–702.
- 37 **Carney IK**, Gibson PG, Murree-Allen K, et al. A systematic evaluation of mechanisms in chronic cough. *Am J Respir Crit Care Med* 1997;**156**:211–6.
- 38 **Jatakanon A**, Laloo UG, Lim S, et al. Increased neutrophils and cytokines, TNF-alpha and IL-8, in induced sputum of non-asthmatic patients with chronic dry cough. *Thorax* 1999;**54**:234–7.
- 39 **Chatkin JM**, Ansarin K, Silkoff PE, et al. Exhaled nitric oxide as a noninvasive assessment of chronic cough. *Am J Respir Crit Care Med* 1999;**159**:1810–3.
- 40 **British Thoracic Society, British Paediatric Association, Royal College of Physicians of London**, et al. Guidelines on the management of asthma. *Thorax* 1993;**48**(Suppl):S1–24.
- 41 **British Thoracic Society, National Asthma Campaign, Royal College of Physicians of London**, et al. British guidelines on asthma management: 1995 review and position statement. *Thorax* 1997;**52**(Suppl 1):S1–21.
- 42 **National Asthma Education and Prevention Programme**. Expert panel report 2. *Guidelines for the diagnosis and management of asthma*, Publication no 97-4051. Bethesda, MD: National Institute of Health, 1997.
- 43 **Society of Pharmaceutical Medicine**. Clinical development of drugs against asthma. Society of Pharmaceutical Medicine expert panel report. *J Pharmaceut Med* 1993;**3**:117–253.
- 44 **Cockcroft DW**, Jovic R, Marciniuk DD, et al. The current dilemma with spirometric inclusion criteria for asthma drug trials. *Ann Allergy Asthma Immunol* 1997;**79**:226–8.
- 45 **Taylor DR**. Making the diagnosis of asthma. *BMJ* 1997;**315**:4–5.
- 46 **Siersted HC**, Mostgaard G, Hyldebrandt N, et al. Interrelationships between diagnosed asthma, asthma-like symptoms, and abnormal airway behaviour in adolescence: the Odense Schoolchild Study. *Thorax* 1996;**51**:503–9.
- 47 **Glauser FL**. Variant asthma. *Ann Allergy* 1972;**30**:457–9.
- 48 **Corrao WM**, Braman SS, Irwin RS. Chronic cough as the sole presenting manifestation of bronchial asthma. *N Engl J Med* 1979;**300**:633–7.
- 49 **Pratter MR**, Bartter T, Akers S, et al. An algorithmic approach to chronic cough. *Ann Intern Med* 1993;**119**:977–83.
- 50 **Niimi A**, Amitani R, Suzuki K, et al. Eosinophilic inflammation in cough variant asthma. *Eur Respir J* 1998;**11**:1064–9.
- 51 **Gibson PG**, Dolovich J, Denburg J, et al. Chronic cough: eosinophilic bronchitis without asthma. *Lancet* 1989;**i**:1346–8.
- 52 **Niimi A**, Matsumoto H, Minakuchi M, et al. Airway remodelling in cough-variant asthma. *Lancet* 2000;**356**:564–5.
- 53 **Brightling CE**, Bradding P, Symon FA, et al. Mast cell infiltration of airway smooth muscle in asthma. *N Engl J Med* 2002;**346**:1699–705.
- 54 **Cheriyian S**, Greenberger PA, Patterson R. Outcome of cough variant asthma treated with inhaled steroids. *Ann Allergy* 1994;**73**:478–80.
- 55 **Brightling CE**, Ward R, Wardlaw AJ, et al. Airway inflammation, airway responsiveness and cough before and after inhaled budesonide in patients with eosinophilic bronchitis. *Eur Respir J* 2000;**15**:682–6.
- 56 **Vathenen AS**, Knox AJ, Wisniewski A, et al. Time course of change in bronchial reactivity with an inhaled corticosteroid in asthma. *Am Rev Respir Dis* 1991;**143**:1317–21.
- 57 **Everard M**. CFC transition: the Emperor's new clothes. Each class drug deserves a delivery system that meets its own requirements. *Thorax* 2000;**55**:811–4.
- 58 **Doan T**, Patterson R, Greenberger PA. Cough variant asthma: usefulness of a diagnostic-therapeutic trial with prednisone. *Ann Allergy* 1992;**69**:505–9.
- 59 **Gibson PG**, Henry RL, Thomas P. Noninvasive assessment of airway inflammation in children: induced sputum, exhaled nitric oxide, and breath condensate. *Eur Respir J* 2000;**16**:1008–15.
- 60 **Dicpinigaitis PV**, Dobkin JB. Effect of zafirlukast on cough reflex sensitivity in asthmatics. *J Asthma* 1999;**36**:265–70.
- 61 **Dicpinigaitis PV**, Dobkin JB, Reichel J. Antitussive effect of the leukotriene receptor antagonist zafirlukast in subjects with cough-variant asthma. *J Asthma* 2002;**39**:291–7.
- 62 **Hwang SW**, Cho H, Kwak J, et al. Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances. *Proc Natl Acad Sci USA* 2000;**97**:6155–60.
- 63 **Fujimura M**, Sakamoto S, Matsuda T. Bronchodilator-resistant cough in atopic patients: bronchial reversibility and hyperresponsiveness. *Intern Med* 1992;**31**:447–52.
- 64 **Fujimura M**, Songur N, Kamio Y, et al. Detection of eosinophils in hypertonic saline-induced sputum in patients with chronic nonproductive cough. *J Asthma* 1997;**34**:119–26.
- 65 **McGarvey LP**, Forsythe P, Heaney LG, et al. Bronchoalveolar lavage findings in patients with chronic nonproductive cough. *Eur Respir J* 1999;**13**:59–65.
- 66 **Ulualp SO**, Toohill RJ. Laryngopharyngeal reflux: state of the art diagnosis and treatment. *Otolaryngol Clin North Am* 2000;**33**:785–802.
- 67 **Belafsky PC**, Postma GN, Koufman JA. Laryngopharyngeal reflux symptoms improve before changes in physical findings. *Laryngoscope* 2001;**111**:979–81.
- 68 **Jack CI**, Walshaw MJ, Tran J, et al. Twenty-four-hour tracheal pH monitoring: a simple and non-hazardous investigation. *Respir Med* 1994;**88**:441–4.
- 69 **Irwin RS**, French CL, Curley FJ, et al. Chronic cough due to gastroesophageal reflux. Clinical, diagnostic, and pathogenetic aspects. *Chest* 1993;**104**:1511–7.
- 70 **Ing AJ**, Ngu MC, Breslin AB. Pathogenesis of chronic persistent cough associated with gastroesophageal reflux. *Am J Respir Crit Care Med* 1994;**149**:160–7.
- 71 **Irwin RS**, Zawacki JK, Curley FJ, et al. Chronic cough as the sole presenting manifestation of gastroesophageal reflux. *Am Rev Respir Dis* 1989;**140**:1294–300.
- 72 **Mittal RK**, Balaban DH. The esophagogastric junction. *N Engl J Med* 1997;**336**:924–32.
- 73 **Dent J**, Dodds WJ, Friedman RH, et al. Mechanism of gastroesophageal reflux in recumbent asymptomatic human subjects. *J Clin Invest* 1980;**65**:256–67.
- 74 **Floyer J**. *A treatise on the asthma*. London, 1698.
- 75 **Ours TM**, Kavuru MS, Schilz RJ, et al. A prospective evaluation of esophageal testing and a double-blind, randomized study of omeprazole in a diagnostic and therapeutic algorithm for chronic cough. *Am J Gastroenterol* 1999;**94**:3131–8.
- 76 **Waring JP**, Lacayo L, Hunter J, et al. Chronic cough and hoarseness in patients with severe gastroesophageal reflux disease. Diagnosis and response to therapy. *Dig Dis Sci* 1995;**40**:1093–7.
- 77 **Kiander TO**, Salomaa ER, Hietanen EK, et al. Chronic cough and gastroesophageal reflux: double-blind placebo-controlled study with omeprazole. *Eur Respir J* 2000;**16**:633–8.
- 78 **Ing AJ**, Ngu MC, Breslin AB. A randomised double-blind placebo controlled crossover study of ranitidine in patients with chronic persistent cough associated with gastroesophageal reflux. *Am Rev Respir Dis* 1992;**145**:A11.
- 79 **Vaezi MF**, Richter JE. Twenty-four-hour ambulatory esophageal pH monitoring in the diagnosis of acid reflux-related chronic cough. *South Med J* 1997;**90**:305–11.
- 80 **Dent J**, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management: the Genval workshop report. *Gut* 1999;**44**:S1–16.
- 81 **DeMeester TR**, Bonavina L, Iacone C, et al. Chronic respiratory symptoms and occult gastroesophageal reflux. A prospective clinical study and results of surgical therapy. *Ann Surg* 1990;**211**:337–45.
- 82 **Irwin RS**, Zawacki JK, Wilson MM, et al. Chronic cough due to gastroesophageal reflux disease. Failure to resolve despite total/near total elimination of esophageal acid. *Chest* 2002;**121**:1132–40.
- 83 **Ing AJ**, Ngu MC, Breslin AB. Chronic persistent cough and gastroesophageal reflux. *Thorax* 1991;**46**:479–83.
- 84 **Sifrim D**, Holloway R, Silny J, et al. Acid, nonacid, and gas reflux in patients with gastroesophageal reflux disease during ambulatory 24-hour pH-impedance recordings. *Gastroenterology* 2001;**120**:1588–98.
- 85 **Vela MF**, Camacho-Lobato L, Srinivasan R, et al. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. *Gastroenterology* 2001;**120**:1599–606.
- 86 **Smyrniotis NA**, Irwin RS, Curley FJ. Chronic cough with a history of excessive sputum production. The spectrum and frequency of causes, key components of the diagnostic evaluation, and outcome of specific therapy. *Chest* 1995;**108**:991–7.
- 87 **Leite LP**, Johnston BT, Just RJ, et al. Persistent acid secretion during omeprazole therapy: a study of gastric acid profiles in patients demonstrating failure of omeprazole therapy. *Am J Gastroenterol* 1996;**91**:1527–31.
- 88 **Pepe PE**, Marini JJ. Occult positive end-expiratory pressure in mechanically ventilated patients with airflow obstruction: the auto-PEEP effect. *Am Rev Respir Dis* 1982;**126**:166–70.

- 89 **Pratter MR**, Bartter T, Lotano R. The role of sinus imaging in the treatment of chronic cough in adults. *Chest* 1999;**116**:1287-91.
- 90 **Irwin RS**, Rosen MJ, Braman SS. Cough. A comprehensive review. *Arch Intern Med* 1977;**137**:1186-91.
- 91 **Brighling CE**, Ward R, Wolmann G, et al. Induced sputum inflammatory mediator concentrations in eosinophilic bronchitis and asthma. *Am J Respir Crit Care Med* 2000;**162**:878-82.
- 92 **Sant'Amrogio G**, Tsabone H, Sant'Amrogio FB. Sensory information from the upper airway: role in the control of breathing. *Respir Physiol* 1995;**102**:1-16.
- 93 **Grossman J**. One airway, one disease. *Chest* 1997;**111**:11-16S.
- 94 **Mello CJ**, Irwin RS, Curley FJ. Predictive values of the character, timing, and complications of chronic cough in diagnosing its cause. *Arch Intern Med* 1996;**156**:997-1003.
- 95 **Bousquet J**, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. *J Allergy Clin Immunol* 2001;**108**:S147-334.
- 96 **Sesoko S**, Kaneko Y. Cough associated with the use of captopril. *Arch Intern Med* 1985;**145**:1524.
- 97 **Inman WH**. Enalapril-induced cough. *Lancet* 1986;**ii**:1218.
- 98 **Yeo WW**, Chadwick IG, Kraskiewicz M, et al. Resolution of ACE inhibitor cough: changes in subjective cough and responses to inhaled capsaicin, intradermal bradykinin and substance P. *Br J Clin Pharmacol* 1995;**40**:423-9.
- 99 **Yeo WW**, Foster G, Ramsay LE. Prevalence of persistent cough during long-term enalapril treatment: controlled study versus nifedipine. *Q J Med* 1991;**80**:763-70.
- 100 **Morice AH**, Lowry R, Brown MJ, et al. Angiotensin-converting enzyme and the cough reflex. *Lancet* 1987;**ii**:1116-8.
- 101 **Ojoo JC**, Kastelik JA, Morice AH. Duration of angiotensin converting enzyme inhibitor induced cough. *Thorax* 2001;**56**(Suppl III):iii72.
- 102 **Hargreaves MR**, Benson MK. Inhaled sodium cromoglycate in angiotensin-converting enzyme inhibitor cough. *Lancet* 1995;**345**:13-16.
- 103 **Fogari R**, Zoppi A, Tettamanti F, et al. Effects of nifedipine and indomethacin on cough induced by angiotensin-converting enzyme inhibitors: a double-blind, randomized, cross-over study. *J Cardiovasc Pharmacol* 1992;**19**:670-3.
- 104 **McEwan JR**, Choudry NB, Fuller RW. The effect of sulindac on the abnormal cough reflex associated with dry cough. *J Pharm Exp Ther* 1990;**255**:161-4.
- 105 **Elliott WJ**. Double-blind comparison of eprosartan and enalapril on cough and blood pressure in unselected hypertensive patients. Eprosartan Study Group. *J Hum Hypertens* 1999;**13**:413-7.
- 106 **Gordon SB**, Curran AD, Turley A, et al. Glass bottle workers exposed to low-dose irritant fumes cough but do not wheeze. *Am J Respir Crit Care Med* 1997;**156**:206-10.
- 107 **Gordon SB**, Curran AD, Fishwick D, et al. Respiratory symptoms among glass bottle workers - cough and airways irritancy syndrome? *Occup Med (Lond)* 1998;**48**:455-9.
- 108 **Hallander HO**, Gnarpe J, Gnarpe H, et al. Bordetella pertussis, Bordetella parapertussis, Mycoplasma pneumoniae, Chlamydia pneumoniae and persistent cough in children. *Scand J Infect Dis* 1999;**31**:281-6.
- 109 **Birkebaek NH**, Kristiansen M, Seefeldt T, et al. Bordetella pertussis and chronic cough in adults. *Clin Infect Dis* 1999;**29**:1239-42.
- 110 **Murphy AC**, Scullion JE, Heubeck CL, et al. Unexplained isolated chronic cough and organ specific autoimmune diseases. A case control-study. *Thorax* 2002;**55**:A61.
- 111 **Lim KH**, Liam CK, Vasudevan AE, et al. Giant cell arteritis presenting as chronic cough and prolonged fever. *Respirology* 1999;**4**:299-301.
- 112 **Larson TS**, Hall S, Hepper NG, et al. Respiratory tract symptoms as a clue to giant cell arteritis. *Ann Intern Med* 1984;**101**:594-7.
- 113 **Poe RH**, Israel RH, Utell MJ, et al. Chronic cough: bronchoscopy or pulmonary function testing? *Am Rev Respir Dis* 1982;**126**:160-2.
- 114 **Hoffstein V**. Persistent cough in nonsmoker. *Can Respir J* 1994;**1**:40-7.
- 115 **Simpson G**. Investigation and management of persistent dry cough. *Thorax* 1999;**54**:469-70.